PCN454 A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.646
https://www.valueinhealthjournal.com/article/S1098-3015(19)33024-4/fulltext
Title :
PCN454 A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33024-4&doi=10.1016/j.jval.2019.09.646
First page :
Section Title :
Open access? :
No
Section Order :
10560